domingo, 21 de agosto de 2016

Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. - PubMed - NCBI

Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. - PubMed - NCBI



 2015 Sep;98(3):309-20. doi: 10.1002/cpt.159. Epub 2015 Jul 22.

Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.

Abstract

Opiate-dependent pregnant women receive opiate maintenance medications to prevent illicit use and withdrawal. Fetal opiate exposure causes central nervous system (CNS) alterations which manifest as postnatal physical withdrawal. The extensive variability in the Neonatal Abstinence Syndrome phenotype remains unexplained and may be related to variability in fetal exposure and response. Improved understanding of functionally significant genetic variants in pathways influencing placental opiate transfer and fetal response can lead to personalized maternal therapy and optimized neonatal outcomes.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

PMID:
 
26058918
 
DOI:
 
10.1002/cpt.159

[PubMed - indexed for MEDLINE]

No hay comentarios:

Publicar un comentario